By Jo Cavallo  / November 2024  / 2024 SITC Annual Meeting

SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer

A phase II study by Riess et al investigating the IO102-IO103 vaccine plus pembrolizumab as first-line treatment in patients with non–small cell lung cancer (NSCLC) showed “promising” overall response...